Department of Gastroenterology, Hepatology, and Nutrition, Children's Mercy.
Department of Pediatrics, School of Medicine, University of Missouri-Kansas City.
Curr Opin Organ Transplant. 2019 Apr;24(2):188-192. doi: 10.1097/MOT.0000000000000620.
The current review provides a summary of available lipid products and discusses current literature and the limitations to the use of various lipid products for treatment and prevention of intestinal failure-associated liver disease (IFALD) in pediatric patients dependent on parenteral nutrition.
Improvements in markers of cholestasis and liver function have been seen with minimizing soybean lipid, fish oil lipid, and mixed fish oil-containing lipid emulsions. Soybean-based lipid products are thought to be the biggest contributor to development of IFALD. Mixed fish oil-containing lipid emulsions are most promising for minimizing and improving IFALD.
Several types of lipid-based products are available for parenteral nutrition. Newer products like the mixed fish oil-containing-based lipid emulsions, that closely mimic the lipid composition provided by enteral feeding, may impact prevention and treatment of IFALD. Limitations exist in the current literature regarding mixed fish oil-containing-based emulsions, as many of the studies were designed to show efficacy with regard to growth, not prevention or treatment of IFALD. Based on available literature, it is reasonable to make some recommendations with regard to product selection for lipid provision.
本综述总结了现有的脂质产品,并讨论了目前关于儿科患者肠衰竭相关肝病(IFALD)的文献和使用各种脂质产品治疗和预防 IFALD 的局限性,这些患者依赖于肠外营养。
通过最小化大豆脂质、鱼油脂质和含混合鱼油的脂质乳剂,胆汁淤积和肝功能的标志物得到了改善。基于大豆的脂质产品被认为是导致 IFALD 发展的最大因素。含混合鱼油的脂质乳剂在最小化和改善 IFALD 方面最有希望。
有几种类型的基于脂质的产品可用于肠外营养。新型产品,如含混合鱼油的基于脂质的乳剂,更接近肠内喂养提供的脂质成分,可能会影响 IFALD 的预防和治疗。目前关于含混合鱼油的基于乳剂的文献存在局限性,因为许多研究旨在显示生长方面的疗效,而不是预防或治疗 IFALD。基于现有文献,对于脂质供应的产品选择,提出一些建议是合理的。